Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
18 studies found for:    CASR
Show Display Options
Rank Status Study
1 Unknown  Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism
Condition: Primary Hyperparathyroidism (PHPT)
2 Recruiting Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations
Conditions: Type 2 Diabetes Mellitus;   Prediabetes (Insulin Resistance, Impaired Glucose Tolerance);   Familiar Hypocalcuric Hypercalcemia;   Healthy Volunteers
Interventions: Device: 1H/ 13C Magnetic Resonance Spectroscopy;   Other: Meal Tolerance Test;   Other: Hyperglycemic-hyperinsulinemic clamp
3 Recruiting A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Condition: Autosomal Dominant Hypocalcemia (ADH)
Intervention: Drug: NPSP795
4 Recruiting The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid
Condition: Hyperparathyroidism, Secondary
Intervention: Drug: calcium sensing receptor agonist
5 Completed Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)
Condition: Transplantation, Stem Cell
Interventions: Drug: Ronacaleret 100 mg;   Drug: Ronacaleret 400 mg;   Drug: Plerixafor
6 Completed An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers
Condition: Bone Marrow Transplantation
Interventions: Drug: Ronacaleret (100mg tablet);   Drug: Placebo
7 Unknown  Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome
Conditions: Hypocalcemia;   Hypercalcemia
8 Completed A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women
Condition: Osteoporosis
Intervention: Drug: SB-751689
9 Completed A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
Condition: Osteoporosis
Intervention: Drug: SB-751689 oral tablets (400 mg)
10 Completed To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females
Conditions: Healthy Volunteer;   Postmenopausal
Intervention: Drug: Ronacaleret
11 Active, not recruiting Hypovitaminosis D : A Link Between Bone/Mineral and Fat/Fuel Metabolism
Conditions: Hypovitaminosis D;   Insulin Resistance;   Obesity;   Osteoporosis
Interventions: Dietary Supplement: Euro D and Ci-CalD;   Dietary Supplement: Euro D, Ci-CalD
12 Completed The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects
Condition: Healthy
Intervention: Drug: cinacalcet
13 Recruiting Effects of PTH Replacement on Bone in Hypoparathyroidism
Conditions: Hypoparathyroidism;   DiGeorge Syndrome
Interventions: Drug: Parathyroid Hormone 1-34;   Drug: PTH 1-34
14 Completed
Has Results
The Effect of Protein on Calcium Absorption and Gastric Acid Production
Condition: Osteoporosis
Interventions: Drug: esomeprazole;   Drug: Placebo
15 Completed CR9112792, a Follow-up of Study CR9108963
Condition: Osteoporosis
Intervention: Procedure: DXA
16 Completed Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.
Condition: Osteoporosis
Interventions: Drug: SB-751689 oral tablets (100 and 400 ng);   Drug: Ketoconazole (NIZORAL) oral tablets (200 mg)
17 Completed The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome
Condition: Metabolic Syndrome
Interventions: Drug: Pioglitazone;   Drug: Telmisartan
18 Completed Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease
Conditions: Vascular Calcification;   Arteriosclerosis
Interventions: Drug: Alendronate;   Drug: Placebo

Indicates status has not been verified in more than two years